Early onset of efficacy in patients with functional and motility-related gastrointestinal disorders: A noninterventional study with Iberogast®

STW 5 (Iberogast®; Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany) contains nine plant extracts and possesses well-documented overall efficacy in functional gastrointestinal disorders (FGID). Little is known about the onset of symptom relief. Twenty-nine centers in Germany recruited 272 patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Raedsch, Richard, Vinson, Bettina, Ottillinger, Bertram, Holtmann, Gerald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820387/
https://www.ncbi.nlm.nih.gov/pubmed/28744774
http://dx.doi.org/10.1007/s10354-017-0578-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820387/
https://www.ncbi.nlm.nih.gov/pubmed/28744774
http://dx.doi.org/10.1007/s10354-017-0578-y

Ejemplares similares